What Biogen's 8-K filings say: 9 filings, latest Oct 28, 2026
Biogen filed its latest 8-K with the SEC on Oct 28, 2026. It discusses acquisition completed and margin pressure.
Public (BIIB)Biotechnology Research10,000+ employeesbiogen.comLinkedIn
Get Biogen's live signals in Claude or ChatGPT, or by API
What changed at Biogen this week? Use Autobound signals for biogen.com.- Filed
- Oct 28, 2026
- Filings
- 9
- Signals
- 27
Source: Autobound Signal API · 76 signals tracked for Biogen · updated
8-K · latest 10
What Biogen's 8-K filings say
- SEC EDGAR
8-K
Filed · 2 signals
Biogen Closes Acquisition of RayThera Inc. Recording $284M in Upfront and IPR&D Expenses
Biogen incurred $284 million of acquired IPR&D, upfront and milestone expense in Q3 2026 primarily related to the stock acquisition of RayThera Inc.
$284M
acquired IPR&D, upfront and milestone expense primarily related to RayThera Inc. acquisition
Biogen reports Q3 GAAP diluted EPS decline to $(0.14) amid higher expenses
Third quarter 2026 GAAP diluted EPS fell 104% to $(0.14), while Non-GAAP diluted EPS declined 46% to $2.62, driven by $284 million in acquired IPR&D, upfront and milestone expenses, as well as higher R&D and SG&A costs.
$284M
acquired IPR&D, upfront and milestone expense primarily related to the acquisition of RayThera Inc.
-104%
decline in GAAP diluted EPS compared to Q3 2025
- SEC EDGAR
8-K
Filed · 3 signals
Biogen to spend up to $484M on R&D acquisitions and licensing deals in Q2 & Q3 2026
Biogen is allocating significant capital for external innovation, with up to $484 million earmarked for acquiring R&D assets and funding collaboration agreements.
$484M
Maximum expected expense for acquired in-process research and development, upfront payments, and milestones across Q2 and Q3 2026 ($164M in Q2 + up to $320M...
Biogen flags up to $484M in R&D charges, pressuring Q2 & Q3 earnings.
Biogen is absorbing a $164M charge in Q2 and forecasts another $290M-$320M in Q3 for R&D deals, significantly impacting profitability.
$484M
Total expected R&D-related charges against earnings for Q2 and Q3 2026 (using $164M for Q2 and high-end $320M for Q3).
Biogen investing over $450M in external R&D acquisitions and partnerships.
Biogen is executing a major capital allocation strategy, spending $164M in Q2 and up to $320M more in Q3 to acquire R&D assets and fund collaborations.
$484M
Total investment in external R&D, including acquisitions and collaborations, across Q2 and Q3 2026 (using $164M for Q2 and high-end $320M for Q3).
- SEC EDGAR
8-K
Filed · 2 signals
The consummation of the merger with Apellis Pharmaceuticals will require significant organizational restructuring to integrate operations, personnel, and technology platforms.
Biogen completes acquisition of Apellis Pharmaceuticals, disclosed on May 14, 2026.
The integration of Apellis Pharmaceuticals will require Biogen to consolidate systems, processes, and personnel across finance, IT, HR, and R&D.
- SEC EDGAR
8-K
Filed · 5 signals
Biogen completes $5.3B acquisition of Apellis Pharmaceuticals, funded by $2B in new debt.
Biogen has completed its acquisition of Apellis, triggering a massive post-merger integration effort.
$5.3B
Aggregate amount paid for the acquisition of Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc.
Biogen completes $5.3B acquisition of Apellis, initiating major post-merger integration.
The acquisition of Apellis for approximately $5.3 billion necessitates a massive integration of all business functions, including IT systems, supply chains, R&D, and sales operations.
$5.3B
Aggregate payment for the acquisition of Apellis Pharmaceuticals
Equiniti Trust Company, LLC
Biogen secures $2B term loan from U.S. Bank to finance Apellis acquisition.
Biogen has taken on $2 billion in new debt, increasing financial scrutiny and the need for robust financial planning, reporting, and treasury management systems.
$2B
New unsecured term loan facilities to finance acquisition
U.S. Bank National AssociationS&P Global RatingsMoody’sBank of America, N.A.
Earlier 8-K filings
Showing 10 of 27 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Biogen with the Signal API
One POST /v1/companies/enrich call with biogen.com returns Biogen 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","signal_types":["sec-8k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.
Same industry
8-K at related companies
Questions about Biogen 8-K
When did Biogen file its latest 8-K?
What did Biogen disclose in its latest 8-K?
Where can I read Biogen's 8-K filing?
Page updated , the date of the newest row on this page.
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .